These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26797240)

  • 1. Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
    Brenner B; Geva R; Rothney M; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Gluzman A; Purim O; Shacham-Shmueli E; Shulman K; Mishaeli M; Man S; Soussan-Gutman L; Tezcan H; Chao C; Shani A; Liebermann N
    Value Health; 2016 Jan; 19(1):82-7. PubMed ID: 26797240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.
    Srivastava G; Renfro LA; Behrens RJ; Lopatin M; Chao C; Soori GS; Dakhil SR; Mowat RB; Kuebler JP; Kim G; Mazurczak M; Lee M; Alberts SR
    Oncologist; 2014 May; 19(5):492-7. PubMed ID: 24710310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer.
    Cartwright T; Chao C; Lee M; Lopatin M; Bentley T; Broder M; Chang E
    Curr Med Res Opin; 2014 Feb; 30(2):321-8. PubMed ID: 24127781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective Evaluation of a 12-Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer.
    Renfro LA; Zhang N; Lopatin M; Chao C; Alberts SR
    Clin Colorectal Cancer; 2017 Mar; 16(1):23-30. PubMed ID: 27600983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
    Yothers G; O'Connell MJ; Lee M; Lopatin M; Clark-Langone KM; Millward C; Paik S; Sharif S; Shak S; Wolmark N
    J Clin Oncol; 2013 Dec; 31(36):4512-9. PubMed ID: 24220557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncotype DX(®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: A review of the evidence.
    You YN; Rustin RB; Sullivan JD
    Surg Oncol; 2015 Jun; 24(2):61-6. PubMed ID: 25770397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs.
    Hornberger J; Lyman GH; Chien R; Meropol NJ
    Value Health; 2012 Dec; 15(8):1014-21. PubMed ID: 23244802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
    Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
    Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
    Jaafar H; Bashir MA; Taher A; Qawasmeh K; Jaloudi M
    Asia Pac J Clin Oncol; 2014 Dec; 10(4):354-60. PubMed ID: 25243360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.
    Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ
    J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatments and clinical outcomes in stage II colon cancer patients with 12-gene Oncotype DX Colon Recurrence Score® assay-guided therapy: real-world data.
    Brenner B; Shulman K; Hubert A; Man S; Geva R; Ben-Aharon I; Fennig S; Mishaeli M; Yarom N; Bar-Sela G; Brenner R; Shai A; Baehner FL; Russell C; Soussan-Gutman L; Voet H; Bareket-Samish A; Liebermann N
    ESMO Open; 2024 Aug; 9(8):103648. PubMed ID: 39137478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
    He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
    Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene-expression signature of tumor recurrence in patients with stage II and III colon cancer treated with 5'fluoruracil-based adjuvant chemotherapy.
    Giráldez MD; Lozano JJ; Cuatrecasas M; Alonso-Espinaco V; Maurel J; Mármol M; Hörndler C; Ortego J; Alonso V; Escudero P; Ramírez G; Petry C; Lasalvia L; Bohmann K; Wirtz R; Mira A; Castells A
    Int J Cancer; 2013 Mar; 132(5):1090-7. PubMed ID: 22833293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
    Venook AP; Niedzwiecki D; Lopatin M; Ye X; Lee M; Friedman PN; Frankel W; Clark-Langone K; Millward C; Shak S; Goldberg RM; Mahmoud NN; Warren RS; Schilsky RL; Bertagnolli MM
    J Clin Oncol; 2013 May; 31(14):1775-81. PubMed ID: 23530100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncotype DX testing does not affect clinical practice in stage IIa colon cancer.
    Allar BG; Messaris E; Poylin VY; Schlechter BL; Cataldo TE
    Med Oncol; 2022 Feb; 39(5):59. PubMed ID: 35150339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.